Response

Affiliations

Comment

Thomas R Fleming. Clin Trials. 2015 Feb.

. 2015 Feb;12(1):21-3.

doi: 10.1177/1740774514563356.

¹ Department of Biostatistics, University of Washington, Seattle, WA, USA tfleming@u.washington.edu.

No abstract available

Comment on

Protecting the confidentiality of interim data: addressing current challenges.
Fleming TR. Fleming TR. Clin Trials. 2015 Feb;12(1):5-11. doi: 10.1177/1740774514561243. Epub 2014 Dec 4. Clin Trials. 2015. PMID: 25475877 Free PMC article.
Commentary: preserving confidentiality of interim data.
Chuang-Stein C, Jiang Q, Marchenko O. Chuang-Stein C, et al. Clin Trials. 2015 Feb;12(1):18-20. doi: 10.1177/1740774514562032. Epub 2014 Dec 5. Clin Trials. 2015. PMID: 25480540 No abstract available.
Commentary: confidentiality of interim trial data-the emerging crisis.
Nissen SE. Nissen SE. Clin Trials. 2015 Feb;12(1):15-7. doi: 10.1177/1740774514561661. Epub 2014 Dec 18. Clin Trials. 2015. PMID: 25525072 No abstract available.
Commentary: data monitoring confidentiality and FDA transparency.
London AJ. London AJ. Clin Trials. 2015 Feb;12(1):12-4. doi: 10.1177/1740774514561047. Epub 2014 Dec 18. Clin Trials. 2015. PMID: 25525073 No abstract available.